Table 2 Chemotherapy
Dosage | EP | Fosaprepitant group | Control group | p-value | |
N = 112 courses | N = 116 courses | ||||
n (%) | n (%) | ||||
Agent | |||||
Carboplatin | 4 | 8 (7.1) | 8 (6.9) | > 0.9999 | |
Cisplatin | 4 | 5 (4.5) | 8 (6.9) | 0.5704 | |
Clofarabine | 3 | 0 (0.0) | 1 (0.9) | > 0.9999 | |
Cyclophosphamide | ≥1 g/m2 | 4 | 2 (1.8) | 2 (1.7) | > 0.9999 |
Cyclophosphamide | < 1 g/m2 | 3 | 19 (17.0) | 18 (15.5) | 0.9072 |
Cytarabine | > 200 mg/m2 to < 3 g/ m2 | 3 | 16 (14.3) | 11 (9.5) | 0.3591 |
Dacarbazine | 4 | 3 (2.7) | 2 (1.7) | 0.6793 | |
Dactinomycin | 4 | 9 (8.0) | 7 (6.0) | 0.6112 | |
Daunorubicin | 3 | 4 (3.6) | 10 (8.6) | 0.1669 | |
Doxorubicin | 3 | 16 (14.3) | 10 (8.6) | 0.2555 | |
Epirubicin | 3 | 2 (1.8) | 0 (0.0) | 0.2402 | |
Etoposide | 3 | 28 (25.0) | 25 (21.6) | 0.6459 | |
Idarubicin | 3 | 1 (0.9) | 0 (0.0) | 0.4912 | |
Ifosfamide | 3 | 17 (15.2) | 12 (10.3) | 0.3701 | |
Irinotecan | 3 | 0 (0.0) | 2 (1.7) | 0.498 | |
Melphalan | > 50 mg/m2 | 3 | 1 (0.9) | 1 (0.9) | 1.0000 |
Methotrexate | ≥250 mg to < 12 g/m2 | 3 | 20 (17.9) | 15 (12.9) | 0.3965 |
Temozolomide | 3 | 0 (0.0) | 1 (0.9) | > 0.9999 | |
Thiotepa | ≥300 mg/m2 | 4 | 1 (0.9) | 0 (0.0) | 0.4912 |
EP (CINV risk) | |||||
3 (> 30–90%) | 84 (75.0) | 89 (76.7) | 0.8812 | ||
4 (> 90%) | 28 (25.0) | 27 (23.3) | |||